explore -WSS

explore

author：comprehensive 2025-10-02 11:10:47 - browse：2487

Illustration of a teal cancer cell. -- health coverage from STAT — Illustration of a teal cancer cell. Adobe

Sana Biotechnology, a startup that just a couple of years ago raised over $1 billion off a grand plan to create a portfolio of powerful medicines, said Tuesday it would lay off nearly a third of its employees and de-prioritize one of its most ambitious programs as it looks to save money.

The layoffs are Sana’s second round of cuts in less than a year. It laid off 15% of staff last November after axing another program.

Tuesday’s move pushed back a program focused on turning a patient’s own immune cells into cancer-killing assassins or curing blood disorders such as sickle cell with just an IV infusion. Known as in vivo reprogramming, it was originally the company’s central focus and would have amounted to a monumental breakthrough.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Apple is now the first public company to be valued at $3 trillion
Next article： Startling documents reveal new facets of Sacklers' opioid empire

hotspot

WSS

Drone hits Crimean ammunition depot as strikes kill, wound civilians and journalists in Ukraine

The response to Covid

How a key Senate committee is planning to regulate PBMs

The response to Covid

Transgender women dream of pregnancy via uterus transplants

Focused ultrasound for uterine fibroids: an uphill battle

explore

explore

focus

Medicare proposal to cover medical devices draws a mixed reaction

Hundreds of thousands march in Israel. Former security chiefs beg Netanyahu to halt legal overhaul

Medical leaders decry Supreme Court decision on affirmative action

Sophia Smith scores twice for US in in 3

Bright Health sells Medicare Advantage business to Molina

First Opinion Podcast: What happens when kids become caregivers?

Medicare details structure of new drug price negotiation program

Do more moles mean more problems? Not so, says new study

Medical records are filled with copy

Drone hits Crimean ammunition depot as strikes kill, wound civilians and journalists in Ukraine

hotspot

Merck to buy EyeBio, maker of eye drug, as it grows pipeline

How to protect coverage of PrEP

Akili, maker of video game for ADHD, to be acquired for 34 million

PrEP can help anyone prevent HIV. Why do so few people take it?

Dark money group runs ads on China biotech bill

Merus drug and Keytruda shrank tumors in patients with head and neck cancer

hotspot

hotspot

entertainment

focus